ADHD :: Shire receives FDA approvable letter for INTUNIV, a nonstimulant ADHD treatment

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist that has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).

HIV :: New amfAR research grants to optimize HIV treatment

amfAR, The Foundation for AIDS Research, will grant almost $1.2 million for 10 new research projects aimed at increasing understanding of the social and biological factors that influence the treatment of HIV/AIDS, Dr. Rowena Johnston, amfAR?s vice president of research.

Mental Health :: Moon jobs will tax mental health of workers

Depression, anxiety, and low productivity will characterize the lunar jobs of tomorrow, says Rutgers-Camden HR scholar. Think your job is tough” Can?t wait for summer vacation to ?get away from it all?” Just wait, says a Rutgers University?Camden researcher. In the not-too-distant future, some jobs will challenge workers placed far, far away from it all.

HIV :: Hepatitis B drug can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack